David G Huntsman

List of Publications by Year
in descending order

253 papers	31,055 citations	4388 86 h-index	4991 167 g-index
267 all docs	267 docs citations	267 times ranked	31353 citing authors

#	Article	IF	Citations
1	The utility of color normalization for <scp>AI</scp>â€based diagnosis of hematoxylin and eosinâ€stained pathology images. Journal of Pathology, 2022, 256, 15-24.	4.5	19
2	Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status. Modern Pathology, 2022, 35, 77-81.	5.5	6
3	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 132-141.	2.5	12
4	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
5	Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention. JAMA Network Open, 2022, 5, e2147343.	5.9	41
6	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	4.5	15
7	Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases. Gynecologic Oncology, 2022, 165, 376-384.	1.4	20
8	Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification. Gynecologic Oncology, 2022, 165, 201-214.	1.4	18
9	The impact of whole genome and transcriptome analysis (<scp>WGTA</scp>) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies. Journal of Pathology: Clinical Research, 2022, 8, 395-407.	3.0	3
10	Solving the genetic aetiology of hereditary gastrointestinal tumour syndromesâ€" a collaborative multicentre endeavour within the project Solve-RD. European Journal of Medical Genetics, 2022, 65, 104475.	1.3	2
11	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
12	Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. Modern Pathology, 2021, 34, 508-518.	5.5	40
13	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206.	5.5	21
14	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. Gynecologic Oncology, 2021, 160, 568-578.	1.4	21
15	Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers. Human Pathology, 2021, 108, 1-11.	2.0	8
16	Genomic analysis of lowâ€grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. Journal of Pathology, 2021, 253, 41-54.	4.5	54
17	Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nature Cancer, 2021, 2, 189-200.	13.2	36
18	Adultâ€type granulosa cell tumor of the ovary: a <scp><i>FOXL2</i></scp>â€centric disease. Journal of Pathology: Clinical Research, 2021, 7, 243-252.	3.0	27

#	Article	IF	Citations
19	ARID1A regulates R-loop associated DNA replication stress. PLoS Genetics, 2021, 17, e1009238.	3.5	40
20	Modelling hereditary diffuse gastric cancer initiation using transgenic mouseâ€derived gastric organoids and singleâ€cell sequencing. Journal of Pathology, 2021, 254, 254-264.	4.5	11
21	Identification of a Locus Near *ULK1* Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	2.5	5
22	STING pathway expression in lowâ€grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?. Journal of Pathology: Clinical Research, 2021, 7, 548-555.	3.0	6
23	Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of *In Vivo* Fallopian Tube Electroporation and CRISPR-Cas9â€"Mediated Genome Editing. Cancer Research, 2021, 81, 5147-5160.	0.9	11
24	Reply to â€œAn alternative miRISC targets a cancerâ€associated coding sequence mutation in FOXL2â€. EMBO Journal, 2021, 40, e107517.	7.8	3
25	FOXL2 in adultâ€type granulosa cell tumour of the ovary: oncogene or tumour suppressor gene?. Journal of Pathology, 2021, 255, 225-231.	4.5	10
26	From biobank and data silos into a data commons: convergence to support translational medicine. Journal of Translational Medicine, 2021, 19, 493.	4.4	11
27	Use of Immunohistochemical Markers (HNF-1Î², Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction. International Journal of Gynecological Pathology, 2020, 39, 344-353.	1.4	14
28	The coming 15Âyears in gynaecological pathology: digitisation, artificial intelligence, and new technologies. Histopathology, 2020, 76, 171-177.	2.9	8
29	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. Journal of Cancer Research and Clinical Oncology, 2020, 146, 97-104.	2.5	29
30	Histotype-specific analysis of acid ceramidase expression in ovarian cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 855-862.	2.8	5
31	Synthesis of diagnostic quality cancer pathology images by generative adversarial networks. Journal of Pathology, 2020, 252, 178-188.	4.5	53
32	Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours. Journal of Pathology, 2020, 252, 201-214.	4.5	31
33	Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncology, The, 2020, 21, e386-e397.	10.7	237
34	Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer. Epidemiology, 2020, 31, 402-408.	2.7	12
35	Proteomic analysis of transitional cell carcinomaâ€"like variant of tubo-ovarian high-grade serous carcinoma. Human Pathology, 2020, 101, 40-52.	2.0	4
36	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthaseâ€"Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. Clinical Cancer Research, 2020, 26, 4402-4413.	7.0	21

#	Article	IF	Citations
37	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43
38	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	6.4	35
39	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	1.4	15
40	The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity. Cancer Research, 2020, 80, 3480-3491.	0.9	19
41	Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada. American Journal of Obstetrics and Gynecology, 2020, 223, 221.e1-221.e11.	1.3	28
42	SWI/SNF Complex Mutations in Gynecologic Cancers: Molecular Mechanisms and Models. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 467-492.	22.4	47
43	Low-grade serous ovarian cancer: State of the science. Gynecologic Oncology, 2020, 156, 715-725.	1.4	74
44	Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. Modern Pathology, 2020, 33, 1595-1605.	5.5	103
45	p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns. Modern Pathology, 2020, 33, 1649-1659.	5.5	17
46	Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer. Nature Communications, 2020, 11, 2020.	12.8	52
47	Small-Cell Carcinoma of the Ovary, Hypercalcemic Type—Genetics, New Treatment Targets, and Current Management Guidelines. Clinical Cancer Research, 2020, 26, 3908-3917.	7.0	82
48	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation, 2020, 130, 2712-2726.	8.2	112
49	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. PLoS ONE, 2020, 15, e0240412.	2.5	1
50	Evaluation of human papillomavirus (HPV) prediction using the International Endocervical Adenocarcinoma Criteria and Classification system, compared to p16 immunohistochemistry and HPV RNA in-situ hybridization. Journal of Pathology and Translational Medicine, 2020, 54, 480-488.	1.1	11
51	Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism. ELife, 2020, 9, .	6.0	19
52	Title is missing!. , 2020, 15, e0240412.		0
53	Title is missing!. , 2020, 15, e0240412.		0
54	Title is missing!. , 2020, 15, e0240412.		0

#	Article	IF	Citations
55	Title is missing!. , 2020, 15, e0240412.		0
56	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
57	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecologic Oncology, 2019, 154, 516-523.	1.4	62
58	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
59	Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. Human Pathology, 2019, 92, 39-47.	2.0	9
60	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	5.5	54
61	Oncogenic mutations in histologically normal endometrium: the new normal?. Journal of Pathology, 2019, 249, 173-181.	4.5	106
62	Base excision repair deficiency signatures implicate germline and somatic <i>MUTYH</i> aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. Journal of Physical Education and Sports Management, 2019, 5, a003681.	1.2	33
63	Germline deletion of ETV6 in familial acute lymphoblastic leukemia. Blood Advances, 2019, 3, 1039-1046.	5.2	21
64	Class I <scp>HDAC</scp> inhibitors enhance <scp>YB</scp> â€‘1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Reports, 2019, 20, e48375.	4.5	78
65	Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target. Cancer Cell International, 2019, 19, 10.	4.1	31
66	A comprehensive geneâ€"environment interaction analysis in Ovarian Cancer using genomeâ€‘wide significant common variants. International Journal of Cancer, 2019, 144, 2192-2205.	5.1	12
67	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22
68	The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. Clinical Cancer Research, 2018, 24, 2328-2341.	7.0	63
69	DICER1 hotâ€‘spot mutations in ovarian gynandroblastoma. Histopathology, 2018, 73, 306-313.	2.9	28
70	TERT promoter mutation in adult granulosa cell tumor of the ovary. Modern Pathology, 2018, 31, 1107-1115.	5.5	49
71	Clear cell carcinomas of the ovary and kidney: clarity through genomics. Journal of Pathology, 2018, 244, 550-564.	4.5	41
72	Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition. Clinical Cancer Research, 2018, 24, 1932-1943.	7.0	51

#	Article	IF	Citations
73	The molecular pathology of cancer: from pan-genomics to post-genomics. Journal of Pathology, 2018, 244, 509-511.	4.5	50
74	A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. BMC Cancer, 2018, 18, 254.	2.6	19
75	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer, 2018, 18, 347.	2.6	67
76	High Frequency of Ovarian Cyst Development in Vhl;Snf5 Mice. American Journal of Pathology, 2018, 188, 1510-1516.	3.8	0
77	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. Journal of Clinical Investigation, 2018, 129, 223-229.	8.2	130
78	Changing Clinical Practice. International Journal of Gynecological Cancer, 2018, 28, 1101-1107.	2.5	6
79	Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type. Molecular Cancer Therapeutics, 2018, 17, 2767-2779.	4.1	50
80	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	3.0	70
81	L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. British Journal of Cancer, 2018, 119, 480-486.	6.4	86
82	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
83	Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. American Journal of Obstetrics and Gynecology, 2018, 219, 172.e1-172.e8.	1.3	27
84	Distinct developmental trajectories of endometriotic epithelium and stroma: implications for the origins of endometriosis. Journal of Pathology, 2018, 246, 257-260.	4.5	14
85	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell, 2018, 173, 1755-1769.e22.	28.9	261
86	Histotype classification of ovarian carcinoma: A comparison of approaches. Gynecologic Oncology, 2018, 151, 53-60.	1.4	54
87	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	6.4	23
88	Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer, 2017, 123, 802-813.	4.1	552
89	Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Annals of Medicine, 2017, 49, 435-447.	3.8	61
90	Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma. Molecular Cancer Research, 2017, 15, 250-258.	3.4	52

#	Article	IF	Citations
91	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nature Genetics, 2017, 49, 856-865.	21.4	220
92	Cancer-Associated Mutations in Endometriosis without Cancer. New England Journal of Medicine, 2017, 376, 1835-1848.	27.0	451
93	The histone methyltransferase <scp>EZH2</scp> is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type. Journal of Pathology, 2017, 242, 371-383.	4.5	78
94	A structured latent model for ovarian carcinoma subtyping from histopathology slides. Medical Image Analysis, 2017, 39, 194-205.	11.6	31
95	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
96	APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. Gynecologic Oncology, 2017, 147, 663-671.	1.4	29
97	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. Journal of Pathology: Clinical Research, 2017, 3, 279-293.	3.0	70
98	Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Science Signaling, 2017, 10, .	3.6	51
99	LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers. Gynecologic Oncology, 2017, 147, 642-647.	1.4	13
100	Dose-Response Association of CD8$^+$ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	7.1	260
101	Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. Scientific Reports, 2017, 7, 10574.	3.3	20
102	ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nature Cell Biology, 2017, 19, 962-973.	10.3	173
103	Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?. Journal of Pathology, 2017, 243, 26-36.	4.5	69
104	FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. Journal of Molecular Diagnostics, 2017, 19, 126-136.	2.8	29
105	The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nature Reviews Cancer, 2017, 17, 65-74.	28.4	235
106	Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation. PLoS ONE, 2017, 12, e0178989.	2.5	11
107	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 2017, 8, 64670-64684.	1.8	7
108	Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small‐cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. Histopathology, 2016, 69, 727-738.	2.9	52

#	Article	IF	Citations
109	BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer. International Journal of Gynecological Cancer, 2016, 26, 825-832.	2.5	42
110	Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma. International Journal of Gynecological Pathology, 2016, 35, 209-221.	1.4	28
111	Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research. Scientific Reports, 2016, 6, 34949.	3.3	100
112	The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecologic Oncology, 2016, 141, 454-460.	1.4	85
113	Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nature Genetics, 2016, 48, 758-767.	21.4	287
114	Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. American Journal of Human Genetics, 2016, 98, 830-842.	6.2	201
115	Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. Journal of the National Cancer Institute, 2016, 108, djw134.	6.3	52
116	Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. Journal of Pathology, 2016, 238, 389-400.	4.5	169
117	The genomic landscape of epithelioid sarcoma cell lines and tumours. Journal of Pathology, 2016, 238, 63-73.	4.5	43
118	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. Modern Pathology, 2016, 29, 1586-1593.	5.5	87
119	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. Gynecologic Oncology, 2016, 143, 46-53.	1.4	153
120	Endometrial Carcinomas with *POLE* Exonuclease Domain Mutations Have a Favorable Prognosis. Clinical Cancer Research, 2016, 22, 2865-2873.	7.0	139
121	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. International Journal of Gynecological Pathology, 2016, 35, 430-441.	1.4	180
122	Rare cancers: a sea of opportunity. Lancet Oncology, The, 2016, 17, e52-e61.	10.7	76
123	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Modern Pathology, 2016, 29, 302-314.	5.5	123
124	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	1.0	37
125	Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction. PLoS ONE, 2016, 11, e0153844.	2.5	17
126	Clinically-inspired automatic classification of ovarian carcinoma subtypes. Journal of Pathology Informatics, 2016, 7, 28.	1.7	7

#	Article	IF	Citations
127	Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. American Journal of Cancer Research, 2016, 6, 2235-2251.	1.4	14
128	Categorization of cancer through genomic complexity could guide research and management strategies. Journal of Pathology, 2015, 236, 397-402.	4.5	4
129	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. American Journal of Surgical Pathology, 2015, 39, 1548-1557.	3.7	70
130	Recurrent <i><scp>DICER1</scp></i> hotspot mutations in endometrial tumours and their impact on <scp>microRNA</scp> biogenesis. Journal of Pathology, 2015, 237, 215-225.	4.5	38
131	Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget, 2015, 6, 37663-37677.	1.8	142
132	Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. International Journal of Gynecological Cancer, 2015, 25, 1187-1193.	2.5	31
133	Inâ€depth molecular profiling of the biphasic components of uterine carcinosarcomas. Journal of Pathology: Clinical Research, 2015, 1, 173-185.	3.0	70
134	Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. Journal of Pathology, 2015, 236, 201-209.	4.5	131
135	Using Somatic Mutations to Guide Treatment Decisions. JAMA Oncology, 2015, 1, 275.	7.1	15
136	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Journal of Physical Education and Sports Management, 2015, 1, a000570.	1.2	92
137	Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. Journal of the National Cancer Institute, 2015, 108, djv428.	6.3	128
138	Cancer genomics: why rare is valuable. Journal of Molecular Medicine, 2015, 93, 369-381.	3.9	8
139	Loss of Sprouty2 in human highâ€grade serous ovarian carcinomas promotes EGFâ€induced Eâ€cadherin downâ€regulation and cell invasion. FEBS Letters, 2015, 589, 302-309.	2.8	9
140	Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology, 2015, 66, 664-674.	2.9	77
141	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline<i>CDH1</i>mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	3.2	479
142	Hereditary Diffuse Gastric Cancer Syndrome. JAMA Oncology, 2015, 1, 23.	7.1	540
143	Enhanced <i>GAB2</i> Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1495-1503.	4.1	26
144	Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer, 2015, 15, 32.	2.6	34

#	ARTICLE	IF	CITATIONS
145	Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer, 2015, 15, 415.	2.6	116
146	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839
147	Systematic analysis of somatic mutations impacting gene expression in 12 tumour types. Nature Communications, 2015, 6, 8554.	12.8	102
148	The Oncogenic Roles of DICER1 RNase IIIb Domain Mutations in Ovarian Sertoli-Leydig Cell Tumors. Neoplasia, 2015, 17, 650-660.	5.3	59
149	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 671-676.	2.5	82
150	Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature, 2015, 518, 422-426.	27.8	545
151	Personalized Oncogenomics: Clinical Experience with Malignant Peritoneal Mesothelioma Using Whole Genome Sequencing. PLoS ONE, 2015, 10, e0119689.	2.5	36
152	Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Rare Diseases (Austin, Tex), 2014, 2, e967148.	1.8	40
153	Germline Mutations in MAP3K6 Are Associated with Familial Gastric Cancer. PLoS Genetics, 2014, 10, e1004669.	3.5	57
154	TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. Genome Research, 2014, 24, 1881-1893.	5.5	322
155	Boveri at 100: Theodor Boveri and genetic predisposition to cancer. Journal of Pathology, 2014, 234, 142-145.	4.5	18
156	A current perspective on the pathological assessment of <i><scp>FOXL</scp>2</i> in adult‐type granulosa cell tumours of the ovary. Histopathology, 2014, 64, 380-388.	2.9	36
157	Immunohistochemical characterization of prototypical endometrial clear cell carcinoma—diagnostic utility of <scp>HNF</scp>‐1β and oestrogen receptor. Histopathology, 2014, 64, 585-596.	2.9	68
158	Diagnostic Value of Next-Generation Sequencing in an Unusual Sphenoid Tumor. Oncologist, 2014, 19, 623-630.	3.7	20
159	Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer, 2014, 14, 982.	2.6	27
160	ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Human Pathology, 2014, 45, 1258-1268.	2.0	34
161	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Modern Pathology, 2014, 27, 128-134.	5.5	218
162	Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. American Journal of Obstetrics and Gynecology, 2014, 210, 471.e1-471.e11.	1.3	236

#	Article	IF	Citations
163	Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nature Genetics, 2014, 46, 427-429.	21.4	298
164	A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer, 2014, 14, 120.	2.6	68
165	Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet Journal of Rare Diseases, 2013, 8, 33.	2.7	38
166	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncology, The, 2013, 14, 853-862.	10.7	335
167	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	21.4	270
168	The Chromatin Remodeling Gene ARID1A Is a New Prognostic Marker in Clear Cell Renal Cell Carcinoma. American Journal of Pathology, 2013, 182, 1163-1170.	3.8	66
169	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with <scp>HER2</scp> targeting in 19% of carcinomas. Journal of Pathology, 2013, 229, 111-120.	4.5	169
170	Familial rhabdoid tumour '<i>avant la lettre</i>'-from pathology review to exome sequencing and back again. Journal of Pathology, 2013, 231, 35-43.	4.5	60
171	An α‐€catenin (<i><scp>CTNNA1</scp></i>) mutation in hereditary diffuse gastric cancer. Journal of Pathology, 2013, 229, 621-629.	4.5	184
172	FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. Modern Pathology, 2013, 26, 860-867.	5.5	74
173	Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas. American Journal of Surgical Pathology, 2013, 37, 1421-1432.	3.7	115
174	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1677-1686.	2.5	70
175	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
176	Distinct evolutionary trajectories of primary high‐€grade serous ovarian cancers revealed through spatial mutational profiling. Journal of Pathology, 2013, 231, 21-34.	4.5	357
177	Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. PLoS ONE, 2013, 8, e72162.	2.5	200
178	Beyond CDH1 Mutations: Causes of Hereditary Diffuse Gastric Cancer. , 2013, , 97-110.		0
179	Recurrent Somatic <i>DICER1</i> Mutations in Nonepithelial Ovarian Cancers. New England Journal of Medicine, 2012, 366, 234-242.	27.0	401
180	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 929-934.	7.1	239

#	ARTICLE	IF	CITATIONS
181	Loss of *ARID1A*-Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian Cancers. International Journal of Gynecological Cancer, 2012, 22, 9-14.	2.5	108
182	It Sounded Like a Good Idea at the Time. Journal of Obstetrics and Gynaecology Canada, 2012, 34, 1127-1130.	0.7	14
183	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncology, The, 2012, 13, 385-394.	10.7	753
184	Use of mutation profiles to refine the classification of endometrial carcinomas. Journal of Pathology, 2012, 228, 20-30.	4.5	261
185	The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature, 2012, 486, 395-399.	27.8	1,778
186	The role of the fallopian tube in ovarian cancer. Clinical Advances in Hematology and Oncology, 2012, 10, 296-306.	0.3	77
187	Molecular Pathology of Ovarian Carcinomas. Surgical Pathology Clinics, 2011, 4, 275-296.	1.7	1
188	FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary. American Journal of Surgical Pathology, 2011, 35, 484-494.	3.7	183
189	Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecologic Oncology, 2011, 121, 407-415.	1.4	225
190	Subtype–specific mutation of *PPP2R1A* in endometrial and ovarian carcinomas. Journal of Pathology, 2011, 223, 567-573.	4.5	114
191	Loss of BAF250a (*ARID1A*) is frequent in high–grade endometrial carcinomas. Journal of Pathology, 2011, 224, 328-333.	4.5	210
192	Using next–generation sequencing for the diagnosis of rare disorders: a family with retinitis pigmentosa and skeletal abnormalities. Journal of Pathology, 2011, 225, 12-18.	4.5	29
193	P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Modern Pathology, 2011, 24, 64-81.	5.5	60
194	Calculator for ovarian carcinoma subtype prediction. Modern Pathology, 2011, 24, 512-521.	5.5	95
195	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 2011, 17, 2538-2548.	7.0	217
196	deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data. PLoS Computational Biology, 2011, 7, e1001138.	3.2	477
197	Periodic Acid-Schiff Is Superior to Hematoxylin and Eosin for Screening Prophylactic Gastrectomies From CDH1 Mutation Carriers. American Journal of Surgical Pathology, 2010, 34, 1007-1013.	3.7	14
198	Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible. American Journal of Surgical Pathology, 2010, 34, 984-993.	3.7	143

#	Article	IF	Citations
199	HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival. Annals of Surgery, 2010, 251, 1107-1116.	4.2	53
200	Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas. International Journal of Gynecological Pathology, 2010, 29, 203-211.	1.4	332
201	Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Breast Cancer Research and Treatment, 2010, 121, 347-354.	2.5	37
202	Pregnancy after prophylactic total gastrectomy. Familial Cancer, 2010, 9, 331-334.	1.9	26
203	The biological and clinical value of p53 expression in pelvic high‑grade serous carcinomas. Journal of Pathology, 2010, 222, 191-198.	4.5	136
204	De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Laboratory Investigation, 2010, 90, 1604-1614.	3.7	66
205	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Journal of Medical Genetics, 2010, 47, 436-444.	3.2	495
206	SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics, 2010, 26, 730-736.	4.1	192
207	<i>ARID1A</i>Mutations in Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, 2010, 363, 1532-1543.	27.0	1,460
208	Type I gamma phosphatidylinositol phosphate kinase modulates invasion and proliferation and its expression correlates with poor prognosis in breast cancer. Breast Cancer Research, 2010, 12, R6.	5.0	51
209	Hereditary Diffuse Gastric Cancer. Cancer Treatment and Research, 2010, 155, 33-63.	0.5	17
210	The Specificity of the FOXL2 c.402C>G Somatic Mutation: A Survey of Solid Tumors. PLoS ONE, 2009, 4, e7988.	2.5	82
211	Germline CDH1 deletions in hereditary diffuse gastric cancer families. Human Molecular Genetics, 2009, 18, 1545-1555.	2.9	185
212	Adult-Type Granulosa Cell Tumors and FOXL2 Mutation. Cancer Research, 2009, 69, 9160-9162.	0.9	58
213	Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situhybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer, 2009, 9, 165.	2.6	68
214	HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer, 2009, 9, 433.	2.6	175
215	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathology, 2009, 22, 469-475.	5.5	125
216	Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature, 2009, 461, 809-813.	27.8	984

#	ARTICLE	IF	CITATIONS
217	Quantification of Epigenetic and Genetic 2nd Hits in CDH1 During Hereditary Diffuse Gastric Cancer Syndrome Progression. Gastroenterology, 2009, 136, 2137-2148.	1.3	142
218	Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary. New England Journal of Medicine, 2009, 360, 2719-2729.	27.0	706
219	A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. American Journal of Surgical Pathology, 2009, 33, 14-21.	3.7	211
220	The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas. International Journal of Gynecological Cancer, 2009, 19, 58-64.	2.5	181
221	Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Research and Treatment, 2008, 107, 249-257.	2.5	179
222	Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Research and Treatment, 2008, 110, 417-426.	2.5	91
223	Hereditary diffuse gastric cancer: association with lobular breast cancer. Familial Cancer, 2008, 7, 73-82.	1.9	117
224	Hereditary diffuse gastric cancer. Cancer, 2008, 112, 2655-2663.	4.1	89
225	Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes and Cancer, 2008, 47, 481-489.	2.8	116
226	Reply to Perner and Rubin. Modern Pathology, 2008, 21, 1056-1057.	5.5	1
227	Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Research, 2008, 10, R86.	5.0	107
228	Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Research, 2008, 10, R6.	5.0	29
229	Hereditary Diffuse Gastric Cancer: Prophylactic Surgical Oncology Implications. Surgical Clinics of North America, 2008, 88, 759-778.	1.5	35
230	Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. PLoS Medicine, 2008, 5, e232.	8.4	675
231	Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 2360.	7.4	394
232	CDH1 Truncating Mutations in the E-Cadherin Gene. Annals of Surgery, 2007, 245, 873-879.	4.2	157
233	Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Modern Pathology, 2007, 20, 1156-1165.	5.5	58
234	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Medicine, 2007, 5, 33.	5.5	52

#	Article	IF	Citations
235	MDM2 protein expression is a negative prognostic marker in breast carcinoma. Modern Pathology, 2006, 19, 69-74.	5.5	62
236	Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecologic Oncology, 2006, 100, 264-270.	1.4	78
237	Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival. Journal of Clinical Oncology, 2006, 24, 5637-5644.	1.6	177
238	Gastric cancer: New genetic developments. Journal of Surgical Oncology, 2005, 90, 114-133.	1.7	176
239	Characterization of a Recurrent Germ Line Mutation of the E-Cadherin Gene: Implications for Genetic Testing and Clinical Management. Clinical Cancer Research, 2005, 11, 5401-5409.	7.0	187
240	Genomic Instability of Human Mammary Epithelial Cells Overexpressing a Truncated Form of EMSY. Journal of the National Cancer Institute, 2005, 97, 1302-1306.	6.3	34
241	Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. Experimental Cell Research, 2005, 310, 99-104.	2.6	51
242	Podocalyxin : A Marker of Blasts in Acute Leukemia. American Journal of Clinical Pathology, 2005, 124, 134-142.	0.7	2
243	The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Modern Pathology, 2004, 17, 690-695.	5.5	123
244	Model of the early development of diffuse gastric cancer in Eâ€cadherin mutation carriers and its implications for patient screening. Journal of Pathology, 2004, 203, 681-687.	4.5	242
245	Mechanisms of monozygotic (MZ) twinning: A possible role for the cell adhesion molecule, E-cadherin. American Journal of Medical Genetics Part A, 2003, 120A, 59-62.	2.4	11
246	E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. Human Molecular Genetics, 2003, 12, 3007-3016.	2.9	79
247	EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer. Cell, 2003, 115, 523-535.	28.9	389
248	Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Human Pathology, 2003, 34, 1001-1008.	2.0	99
249	Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Human Molecular Genetics, 2003, 12, 575-582.	2.9	167
250	Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Human Mutation, 2002, 19, 510-517.	2.5	153
251	Early Gastric Cancer in Young, Asymptomatic Carriers of Germ-Line E-Cadherin Mutations. New England Journal of Medicine, 2001, 344, 1904-1909.	27.0	420
252	A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nature Genetics, 2000, 26, 362-364.	21.4	152

#	Article	IF	Citations
253	A New Method for Characterization and Epitope Determination of a Lupus Anticoagulant–Associated Neutralizing Antiprothrombin Antibody. American Journal of Clinical Pathology, 1997, 107, 197-205.	0.7	18